Thubilux Pharma SpA has received a structured loan of US$2.7 million from a leading Italian bank
Tubilux Pharma SpA has successfully raised funds through a structured loan from Cassa Depositi e Prestiti SpA and Banca Intesa San Paolo SpA to support an investment plan for a new production facility which has all the FDA requirements to enter the USA market.
Tubilux Pharma is a leading, privately-held ophthalmic and pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products, with distribution in approximately 30 countries. The firm's customers are large multinational pharmaceutical companies that outsource their production of ophthalmic products to specialized manufactures through medium-term supply contracts (3-5 years).
Oaklins' team in Italy advised Thubilux Pharma SpA in the structuring, negotiation and closing of a long-term debt financing from a leading Italian bank, backed by Cassa Depositi e Prestiti.
Talk to the deal team
Related deals
Bayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreSurcos has completed a liability managament process
The shareholders of Surcos have completed a liability management process, which includes the issuance of US$5 million and a debt exchange totaling US$20 million.
Learn moreVivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn more